Incorporation of bevacizumab to preoperative regional chemotherapy (CT) failed to increase the volume of intraoperative blood loss and the frequency of postoperative complications. Addition of the drug in the regional CT group significantly enhanced the rate of its effect up to 64 % and that of grade III medical pathomorphism up to 55 %. Regardless of the pattern of surgeries, the rate of complications after extended hepatectomy did not differ significantly in the treatment groups. Irrespective of treatment, the rate of acute liver failure rose when the volume of surgery was increased from conventional hemihepatectomy to extended hemihepatectomy. Acute liver failure was prominent (21%) among the complications in the treatment group. The highest incidence of acute liver failure in the comparable groups was observed in the preoperative regional CT group
